Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Shares of Vaccine-Makers Slip as Omicron Threat Wanes, Rivals Emerge

Published 12/23/2021, 12:29 PM
Updated 12/23/2021, 12:34 PM
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Shares of vaccine-makers traded lower Thursday as the threat from omicron wanes and competition gets more intense.

Novavax stock (NASDAQ:NVAX) dropped 3.1% while Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) all traded down 1.5-2%. AstraZeneca ADRs (NASDAQ:AZN) were trading weaker by just under 1%.

Johnson & Johnson (NYSE:JNJ), which is now a distant player in Covid management, was up 0.2%. Contribution of Covid-vaccine sales in the consumer giant’s overall revenue is negligible.

Omicron kept the world on tenterhooks last two months as the variant spread at least twice as fast as delta, the coronavirus mutant that ravaged the world April-September. In no time did it cover more than 80 countries, with nations that had a healthy pace of vaccinations, reporting record number of new cases. Fresh Covid cases in U.K. numbered more than 90,000 last week on some days.

However, it didn’t reflect in increased hospitalizations and latest studies suggest it may not be as deadly as delta, leading to subdued sentiment for stocks of vaccine-makers.

To add to that, the USFDA has approved anti-Covid pills made by Pfizer and Merck. While being no substitute, hope for any sort of medication other than vaccines, particularly among those still hesitant to get a shot, was also adding to the pressure on the stocks. Merck (NYSE:MRK) traded 0.4% lower in the session underway today.

With Novavax getting approved by the European drugs regulator and the WHO earlier this week, prospects of another vaccine compounded the negative sentiment for these stocks. Novavax reported today that a two-dose regimen of their vaccine offers strong protection against omicron and other Covid variants.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.